This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Gradishar WJ , Anderson BO , Balassanian R , Blair SL , Burstein HJ , Cyr A , Elias AD , Farrar WB , Forero A , Giordano SH , Goetz M , Goldstein LJ , Hudis CA , Isakoff SJ , Kelly Marcom P , Mayer IA , McCormick B , Moran M , Patel SA , Pierce LJ , Reed EC , Salerno KE , Schwartzberg LS , Smith KL , Smith ML , Soliman H , Somlo G , Telli M , Ward JH , Shead DA , Kumar R
Invasive breast cancer version 1.2016
JNCCN Journal of the National Comprehensive Cancer Network. 2016 Mar;14(3) :324-354
PMID: 26957618 URL: https://www.scopus.com/inward/record.url?eid=2-s2.0-84961577176&partnerID=40&md5=cd480174ef7f95b25f3b5742f8a4abb1
AbstractBreast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.
NotesExport Date: 3 May 2016